pyrotinib
Showing 1 - 25 of 62
Breast Cancer Invasive Trial (pyrotinib)
Not yet recruiting
- Breast Cancer Invasive
- pyrotinib
- (no location specified)
Jun 18, 2023
Breast Cancer Trial in Taizhou (Pyrotinib)
Recruiting
- Breast Cancer
- Pyrotinib
-
Taizhou, Zhejiang, ChinaTaizhou Hospital
May 26, 2023
Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)
Not yet recruiting
- Breast Cancer
- Pyrotinib
- +2 more
- (no location specified)
Apr 22, 2023
HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)
Recruiting
- HER2-positive Breast Cancer
- Pyrotinib
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 26, 2023
Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)
Recruiting
- Breast Cancer
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023
NSCLC Trial in Beijing (Pyrotinib)
Recruiting
- Non-small Cell Lung Cancer
- Pyrotinib
-
Beijing, Beijing, ChinaPeking Union Medical College
Feb 20, 2023
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line
Recruiting
- Breast Neoplasms
- Inetetamab
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial People's Hospital
Mar 16, 2023
Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer
Not yet recruiting
- HER2-positive Breast Cancer
- Pyrotinib
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Sep 28, 2022
NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)
Not yet recruiting
- Non-small Cell Lung Cancer
- RC48-ADC
- Pyrotinib
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Feb 16, 2023
HER2 Positive Metastatic Breast Cancer Trial in Beijing (pyrotinib, , Capecitabine)
Active, not recruiting
- HER2 Positive Metastatic Breast Cancer
- pyrotinib
- +2 more
-
Beijing, China307 Hospital Affiliated to Academy Military Medical Science
Oct 24, 2022
Breast Cancer Trial in Tianjin (Dalpiciclib, Pyrotinib, Fulvestrant)
Not yet recruiting
- Breast Cancer
- Dalpiciclib
- +2 more
-
Tianjin, ChinaTianjin Cancer Hospital
Mar 28, 2023
HER2-positive Breast Cancer Trial in Shenyang (SHR-A1811, Pyrotinib)
Not yet recruiting
- HER2-positive Breast Cancer
- SHR-A1811
- Pyrotinib
-
Shenyang, Liaoning, ChinaShengjing Hospital affiliated to China Medical University
Dec 1, 2022
Locally Advanced Breast Cancer Trial in Shanghai (pyrotinib)
Recruiting
- Locally Advanced Breast Cancer
- pyrotinib
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 11, 2022
Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)
Not yet recruiting
- Breast Cancer
- Pyrotinib
- +7 more
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Dec 2, 2022
Advanced Breast Cancer Trial (pyrotinib)
Not yet recruiting
- Advanced Breast Cancer
- pyrotinib
- (no location specified)
Feb 16, 2022
Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in
Recruiting
- Breast Cancer
- Pyrotinib
-
Zhejiang, Hangzhou, ChinaChina
Feb 13, 2022
Metastatic Breast Cancer Trial in Zhengzhou (Pyrotinib, SHR6390)
Active, not recruiting
- Metastatic Breast Cancer
- Pyrotinib
- SHR6390
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Mar 7, 2022
HER2-positive Breast Cancer Trial in Xi'an (Pyrotinib)
Recruiting
- HER2-positive Breast Cancer
- Pyrotinib
-
Xi'an, Shaanxi, ChinaJin Yang
Jun 18, 2022
Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)
Active, not recruiting
- Breast Cancer Invasive
- Pyrotinib
- +7 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022
Breast Cancer Trial in Shanghai (Letrozole, Pyrotinib, Dalpiciclib(SHR6390))
Recruiting
- Breast Cancer
- Letrozole
- +3 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jan 21, 2022
Gastric Tumors, Gastroesophageal Junction Adenocarcinoma Trial in Shanghai (Camrelizumab, Pyrotinib, Capecitabine)
Not yet recruiting
- Gastric Neoplasms
- Gastroesophageal Junction Adenocarcinoma
- Camrelizumab
- +5 more
-
Shanghai, China270 Dongan Road, Fudan University Shanghai Cancer Center
Oct 27, 2021
Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer Trial in Shanghai (Palbociclib, trastuzumab, pyrotinib)
Recruiting
- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
- Palbociclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Hospital
Sep 29, 2021
Metastatic Breast Cancer Trial in Zhengzhou (SHR-A1811, Pyrotinib, Bevacizumab)
Not yet recruiting
- Metastatic Breast Cancer
- SHR-A1811
- +2 more
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Mar 13, 2023
Colorectal Cancer Trial in Hangzhou (Pyrotinib, Pyrotinib in combination with trastuzumab)
Recruiting
- Colorectal Cancer
- Pyrotinib
- Pyrotinib in combination with trastuzumab
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated hospital of Zhejiang University School of
Jul 13, 2021
Metastatic Breast Cancer Trial (Pyrotinib, Vinorelbine, Inetetamab)
Not yet recruiting
- Metastatic Breast Cancer
- Pyrotinib
- +2 more
- (no location specified)
Jul 11, 2021